Sage Journals: Discover world-class research

Abstract

This study was a prospective, randomized, open, crossover study comparing a double dose (DD) of normal-release (NR) morphine at bedtime with a single dose (SD) of NR morphine at bedtime and 4 h later. Twenty patients completed the study. Four patients required breakthrough analgesia during the SD phase of the study, whilst 11 patients required breakthrough analgesia during the DD phase of the study (P=0.016). Moreover, all of the pain scores were worse during the DD phase (overnight pain, P <0.01; morning pain, P<0.01), and some of the opioid-related side effect scores were worse during the DD phase (xerostomia, P=0.033; vivid dreams, P=0.05). This study does not support the European Association for Palliative Care (EAPC) recommendations on the use of a double dose of NR morphine at bedtime.

Keywords

dose response relationship drug guidelines morphine

Get full access to this article

View all access options for this article.

References

Hanks GW , de Conno F , Ripamonti C , et al. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823–826.

Hanks GW , de Conno F , Cherny N , et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587–593.

Twycross RG , Lack SA . Symptom control in far advanced cancer: pain relief. London: Pitman Books, 1983.

Twycross R . Pain relief in advanced cancer. Edinburgh: Churchill Livingstone, 1994.

Houde RW , Wallenstein SL , Beaver WT . Clinical measurement of pain. In deStevens G ed. Analgetics. New York: Academic Press, 1965: 75–122.

Daut RL , Cleeland CS , Flanery RC . Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197–210.

Serlin RC , Mendoza TR , Nakamura Y , Edwards KR , Cleeland CS . When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277–284.

Labrecque G , Vanier M-C . Biological rhythms in pain and in the effects of opioid analgesics. Pharmacol Ther 1995; 68: 129–147.

Labrecque G , Karzazi M , Vanier M-C . Biological rhythms in pain and analgesia. In Redfern PH , Lemner B eds. Physiology and pharmacology of biological rhythms. Berlin: Springer-Verlag, 1997: 619–649.

10.

Sittl R , Kamp HD , Knoll R . Zirkadiane rhythmik des schmerzempfindens bei tumorpatienten. Nevenheilkunde 1990; 9: 22–24.

11.

Wilder-Smith CH , Schimke J , Bettiga A . Circadian pain responses with tramadol (T), a short-acting opioid and alpha-adrenergic agonist, and morphine (M) in cancer pain. In Biological rhythms and medication. Proceedings of the 5th International Conference on Chronopharmacology, 1992 July 12–16, Amelia Island, USA. (abstract XIII-6).

12.

Wilder-Smith CH , Wilder-Smith OH . Diurnal patterns of pain in cancer patients during treatment with long-acting opioid analgesics. In Biological rhythms and medication. Proceedings of the 5th International Conference on Chronopharmacology; 1992 July 12–16; Amelia Island, USA. (abstract XIII-7).

13.

Bruera E , Macmillan K , Kuehn N , Miller MJ . Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain 1992; 49: 311–314.

14.

Citron ML , Kalra JM , Seltzer VL , Chen S , Hoffman M , Walczak MB . Patient-controlled analgesia for cancer pain: a long-term study of inpatient and outpatient use. Cancer Invest 1992; 10: 335–341.

15.

Gourlay GK , Plummer JL , Cherry DA . Chronopharmaco-kinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 1995; 61: 375–381.

16.

World Health Organization . Cancer pain relief, second edition. Geneva: WHO, 1996.

An assessment of the efficacy and tolerability of a ‘double dose’ of normal-release morphine sulphate at bedtime

Abstract

Keywords

Get full access to this article

References